Assessing the Use of JAK Inhibitors in Atopic Dermatitis Management
Lisa Swanson, MD; Linda Stein Gold, MD; James Song, MD, and James Del Rosso, DO, examine comprehensive approaches to managing moderate to severe atopic dermatitis, with particular focus on JAK inhibitor therapy selection, safety monitoring, and clinical decision-making through detailed analysis of patient cases, therapeutic advances, and emerging research.
EP. 1: Determining Atopic Dermatitis Severity and When to Advance to Systemic Therapy
February 28th 2025Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.
EP. 2: Optimizing Disease Control and AAD Guidelines for Systemic Therapies
February 28th 2025Panelists discuss how physicians can achieve optimal atopic dermatitis management by following American Academy of Dermatology (AAD) guidelines for systemic therapy selection while considering individual patient factors and treatment goals.
EP. 3: Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis
March 7th 2025Panelists discuss how clinicians can choose the most appropriate systemic treatment for moderate to severe atopic dermatitis by evaluating patient characteristics, comorbidities, and therapeutic goals while considering the latest clinical evidence.
EP. 8: Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
March 21st 2025Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
